Synthio Labs, a rising voice-AI startup in the life sciences sector, has secured a $5 million seed round led by Elevation Capital, along with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and several angel investors. The funding marks a strong vote of confidence in the company’s mission to transform how pharmaceutical companies, doctors, and patients communicate. With healthcare communication often slow, manual, and difficult to scale, Synthio Labs aims to build an AI-driven solution that works faster, responds better, and improves human connection across the healthcare ecosystem.
Building Smarter Voice AI for Life Sciences
Synthio Labs specialises in clinical-grade voice AI, designed specifically for the complex needs of life sciences organisations. Instead of using generic AI, the company has created an operating system that understands medical language, doctor interactions, and patient behaviour. This helps pharma teams engage with their audience in a more precise and meaningful way. One of their key products, Jarvis, works as an AI co-pilot for field teams. It assists medical representatives as they meet doctors, helping them record insights, analyse conversations, and stay updated in real time. Another major tool, Ather, acts as a multi-channel engine that supports communication with doctors and patients across voice calls, chat, and other digital channels. Their third product, Simulation Studio, builds “digital twins” of real doctors and patients, allowing life sciences teams to simulate conversations, research behaviour patterns, and plan strategies with higher accuracy. Together, these products form a powerful AI ecosystem aimed at modernising how healthcare communication happens.
Why Investors Are Backing the Vision
The $5 million funding round gives Synthio Labs the runway it needs to strengthen its technology and move deeper into global markets. Investors believe that the company is addressing a major gap in the healthcare industry. Most communication between pharma teams, doctors, and patients is still manual, time-consuming, and difficult to scale. Synthio’s AI can perform these tasks faster while maintaining the accuracy and personal touch required in medical communication. The company has already demonstrated its capabilities in real-world conditions. In one example, a pharmaceutical firm used Synthio’s voice AI to connect with 5,000 eczema patients in just 48 hours. The AI handled onboarding, screening, and support calls with speed and consistency, showing that the system can operate at scale without losing quality. This level of performance has strengthened confidence among investors who see a clear path for Synthio to become a major infrastructure layer for global life sciences engagement.
A Young Team with a Big Mission
Synthio Labs was founded in 2024 by Supreet Deshpande, Rajashekar Vasantha, and Sahitya Sridhar. Supreet leads the company as CEO, while Rajashekar serves as CTO and Sahitya drives product innovation. The founders bring strong experience in AI, healthcare, and enterprise technology, shaping the company’s vision to make healthcare communication more human, intelligent, and dependable. Their goal is not just to build advanced AI tools but to enable life sciences teams to improve real patient outcomes through better engagement. The fresh capital will help Synthio expand its engineering team, scale its platform in the US and Europe, and deepen partnerships with large pharma companies. With rapid growth and a clear mission, Synthio Labs is positioning itself as a global leader working at the intersection of AI and healthcare communication.